Results
|
1.
|
|
|
2.
|
|
|
3.
|
|
|
4.
|
|
|
5.
|
|
|
6.
|
|
|
7.
|
|
|
8.
|
|
|
9.
|
|
|
10.
|
|
|
11.
|
|
|
12.
|
|
|
13.
|
|
|
14.
|
|
|
15.
|
Identifying pancreatic cancer patients for targeted treatment: the challenges and limitations of the current selection process and vision for the future. [electronic resource] by
- Showalter, Shayna L
- Charles, Sarah
- Belin, Justin
- Cozzitorto, Joseph
- Einstein, Peter
- Richards, Nathan G
- Sauter, Patricia K
- Kennedy, Eugene P
- Witkiewicz, Agnes
- Brody, Jonathan R
- Yeo, Charles J
Producer: 20100603
In:
Expert opinion on drug delivery vol. 7
Availability: No items available.
|
|
16.
|
HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients. [electronic resource] by
- Richards, Nathan G
- Rittenhouse, David W
- Freydin, Boris
- Cozzitorto, Joseph A
- Grenda, Dane
- Rui, Hallgeir
- Gonye, Greg
- Kennedy, Eugene P
- Yeo, Charles J
- Brody, Jonathan R
- Witkiewicz, Agnieszka K
Producer: 20100928
In:
Annals of surgery vol. 252
Availability: No items available.
|
|
17.
|
pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs. [electronic resource] by
- Williams, Timothy K
- Costantino, Christina L
- Bildzukewicz, Nikolai A
- Richards, Nathan G
- Rittenhouse, David W
- Einstein, Lisa
- Cozzitorto, Joseph A
- Keen, Judith C
- Dasgupta, Abhijit
- Gorospe, Myriam
- Gonye, Gregory E
- Yeo, Charles J
- Witkiewicz, Agnieszka K
- Brody, Jonathan R
Producer: 20110427
In:
PloS one vol. 5
Availability: No items available.
|